Sign in
Stories
Ethris' Virus-Induced Asthma Treatment
Share
Advancements in Antibodies to Protect Im...
CDC Revises COVID Guidelines
COVID Vaccines and Long COVID Link
COVID Reporting Requirements Expire
Evaxion Biotech Closes Public Offering
Livestock Vaccine Market Booms
Overview
API
Ethris initiates Phase 1 study for virus-induced asthma treatment, leveraging its proprietary technology platform. The lead candidate, ETH47, aims to induce mucosal innate immune responses at viral entry sites, potentially addressing pandemic preparedness against influenza and SARS-CoV-2.
Ask a question
How does the involvement of Bayern Innovativ and the UK trial site reflect international collaboration in healthcare innovation?
How might Ethris' technology platform impact the broader field of mRNA-based therapies?
What are the potential challenges in developing effective treatments for virus-induced asthma?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Sep 2023
Oct 2023
Nov 2023
Coverage